Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia
Latest Information Update: 14 Aug 2025
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ELBRUS
- Sponsors AstraZeneca
Most Recent Events
- 08 May 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 08 May 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Jun 2026.
- 27 Sep 2024 Status changed from not yet recruiting to recruiting.